PT788480E - Cristalizacao de levobupivacaina e seus analogos - Google Patents

Cristalizacao de levobupivacaina e seus analogos

Info

Publication number
PT788480E
PT788480E PT95934738T PT95934738T PT788480E PT 788480 E PT788480 E PT 788480E PT 95934738 T PT95934738 T PT 95934738T PT 95934738 T PT95934738 T PT 95934738T PT 788480 E PT788480 E PT 788480E
Authority
PT
Portugal
Prior art keywords
pct
levobupivacaine
analogs
crystallization
sec
Prior art date
Application number
PT95934738T
Other languages
English (en)
Inventor
Marianne Langston
Benjamin Mark Skead
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421476A external-priority patent/GB9421476D0/en
Priority claimed from GBGB9504926.8A external-priority patent/GB9504926D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of PT788480E publication Critical patent/PT788480E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
PT95934738T 1994-10-25 1995-10-23 Cristalizacao de levobupivacaina e seus analogos PT788480E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421476A GB9421476D0 (en) 1994-10-25 1994-10-25 Process and salt
GBGB9504926.8A GB9504926D0 (en) 1995-03-10 1995-03-10 Crystallisation

Publications (1)

Publication Number Publication Date
PT788480E true PT788480E (pt) 2003-12-31

Family

ID=26305863

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95934738T PT788480E (pt) 1994-10-25 1995-10-23 Cristalizacao de levobupivacaina e seus analogos

Country Status (16)

Country Link
US (1) US5994548A (pt)
EP (1) EP0788480B1 (pt)
JP (1) JP3911545B2 (pt)
AT (1) ATE245629T1 (pt)
AU (1) AU698637B2 (pt)
CA (1) CA2200355C (pt)
DE (1) DE69531356T2 (pt)
DK (1) DK0788480T3 (pt)
ES (1) ES2202375T3 (pt)
FI (1) FI117438B (pt)
HU (1) HU227420B1 (pt)
MX (1) MX9703024A (pt)
NO (1) NO309266B1 (pt)
PL (1) PL183210B1 (pt)
PT (1) PT788480E (pt)
WO (1) WO1996012699A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0002246A (pt) * 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
BRPI0104491B8 (pt) * 2001-10-10 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda n-(2,6-dimetilfenil)-1-propil-2-piperidinocarboxamida; processo de obtenção dos enantiômeros; mistura não racêmica dos anantiômeros e seu processo de obtenção e composição farmacêutica.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP1575569B1 (en) 2002-12-13 2010-09-29 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US7094812B2 (en) * 2003-04-24 2006-08-22 Xerox Corporations Colorant compositions
US6790267B1 (en) * 2003-04-24 2004-09-14 Xerox Corporation Colorant compositions
SI2767292T1 (sl) 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007123405A1 (en) * 2006-04-25 2007-11-01 Dishman Pharmaceuticals And Chemicals Ltd. Ropivacaine hydrochloride anhydrate and the preparation thereof
DK2117521T3 (da) 2006-11-03 2012-09-03 Durect Corp Transdermale indgivelsessystemer omfattende bupivacain
US8415401B2 (en) 2007-12-06 2013-04-09 Durect Corporation Oral pharmaceutical dosage forms
DK2234974T3 (da) * 2008-01-15 2012-06-25 Pharmathen Sa Fremgangsmåde til fremstilling af (S)-1-alkyl-2',6'-pipecoloxylidid-forbindelse
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN103073484B (zh) * 2013-01-28 2014-10-22 山东诚创医药技术开发有限公司 一种甲哌卡因及其光学对映体的制备方法
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
BR112019013192A2 (pt) * 2016-12-26 2019-12-10 Cellix Bio Private Ltd composto e composição farmacêutica
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE341404B (pt) * 1967-05-18 1971-12-27 Sterling Drug Inc
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide

Also Published As

Publication number Publication date
PL183210B1 (pl) 2002-06-28
JPH10507464A (ja) 1998-07-21
CA2200355C (en) 2007-03-06
AU698637B2 (en) 1998-11-05
NO309266B1 (no) 2001-01-08
EP0788480B1 (en) 2003-07-23
FI117438B (fi) 2006-10-13
WO1996012699A1 (en) 1996-05-02
PL319829A1 (en) 1997-09-01
FI971711A (fi) 1997-04-22
US5994548A (en) 1999-11-30
NO971903D0 (no) 1997-04-24
NO971903L (no) 1997-04-24
DE69531356T2 (de) 2004-05-27
MX9703024A (es) 1997-10-31
EP0788480A1 (en) 1997-08-13
ATE245629T1 (de) 2003-08-15
HUT77631A (hu) 1998-06-29
DK0788480T3 (da) 2003-09-29
CA2200355A1 (en) 1996-05-02
FI971711A0 (fi) 1997-04-22
HU227420B1 (en) 2011-05-30
JP3911545B2 (ja) 2007-05-09
ES2202375T3 (es) 2004-04-01
DE69531356D1 (de) 2003-08-28
AU3704895A (en) 1996-05-15

Similar Documents

Publication Publication Date Title
PT788480E (pt) Cristalizacao de levobupivacaina e seus analogos
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
ATE166534T1 (de) Germicide wirkstoffkombinationen
DE3880047D1 (de) Zusammensetzung eines zusatzes.
DK393288A (da) Praeparat til saarheling og knogleregenerering
DK0581959T3 (da) Anvendelse af makrolidforbindelser til øjensygdomme
ATE57176T1 (de) Verfahren zur herstellung von (2,2)-paracyclophan und dessen abkoemmlinge.
ATE153022T1 (de) 3',5'-ditertbutyl-4'-hydroxyflavone, verfahren zu ihrer herstellung und pharmazeutische zusammensetzung mit antioxidations- und antivasokonstriktionsaktivität
ES2140565T3 (es) Nuevos derivados de pirazina-carboxamida, su preparacion y su utilizacion en medicamentos.
DE69109401D1 (de) Wässrige Zusammensetzungen zur Behandlung von porösen Substraten.
FI951511A (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
ATE81976T1 (de) 2-pyrimidinyl-1-piperazin-derivate zur behandlung von alkoholismus.
DE59105224D1 (de) Verfahren zur Herstellung von N-substituierten Pyrrolidonen.
DE69103913T2 (de) Verfahren zur Herstellung von Dodekandicarbonsäure.
ES2106680B1 (es) Composiciones acuosas conteniendo ciprofloxacino y utilizacion y procedimiento correspondientes.
DE3764330D1 (de) 2,2;6,6-diethylen-3-oxo-17alpha-pregn-4-en-21, 17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharm. praeparate.
DE3750747T2 (de) Chemische Behandlung von Likören.
DE69103294T2 (de) Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten.
DE59303525D1 (de) Verfahren zur Herstellung von N-(2-Hydroxypropyl)-2,6-dimethylmorpholin
DE68928788D1 (de) Verfahren zur Herstellung von optisch aktiven 3,4-Dihydroxybuttersäurederivaten
ATE165344T1 (de) Herstellung von symmetrischen und unsymmetrischen disubstituierten n-cyandithioiminocarbonaten
ES2065843B1 (es) Aplicacion de ent-11 , 16-dihidroxi-18-nor-4a -carboximetil-oxido de manoilo como inhibidor de la adenilatociclasa.
KR890001568A (ko) 돼지 이질의 예방 및 치료제
YU49004B (sh) LANOSTA-7,9-DIEN-3Гџ, 32-DIOL I POSTUPAK ZA NJEGOVO DOBIJANJE
RO95818A2 (ro) Dezinfectant de uz medical